Vasomotor Symptoms (VMS)
7
2
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
1 terminated out of 7 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
Impact of Lean Pork on Endothelial Function in Perimenopause
Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor
Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)